Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Harvard Business School
Accenture
Daiichi Sankyo
Mallinckrodt
Farmers Insurance
Johnson and Johnson
Cipla

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021875

« Back to Dashboard

NDA 021875 describes NUVIGIL, which is a drug marketed by Cephalon and is included in one NDA. It is available from ten suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the NUVIGIL profile page.

The generic ingredient in NUVIGIL is armodafinil. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the armodafinil profile page.
Summary for 021875
Tradename:NUVIGIL
Applicant:Cephalon
Ingredient:armodafinil
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021875
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NUVIGIL armodafinil TABLET;ORAL 021875 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-3090 0093-3090-56 30 TABLET in 1 BOTTLE (0093-3090-56)
NUVIGIL armodafinil TABLET;ORAL 021875 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-3092 0093-3092-56 30 TABLET in 1 BOTTLE (0093-3092-56)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Jun 15, 2007TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 18, 2024Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:May 29, 2024Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Mar 26, 2009TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 18, 2024Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021875

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-005 Mar 26, 2009 ➤ Sign Up ➤ Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-001 Jun 15, 2007 ➤ Sign Up ➤ Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-002 Mar 26, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Cantor Fitzgerald
Medtronic
Daiichi Sankyo
Covington
Mallinckrodt
Merck
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.